Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193063
Status:
COMPLETED
Last Update Posted:
2014-03-12
First Post:
2005-09-12
Brief Title:
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 HER2 Positive Metastatic Breast Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Organization Data
Organization:
SCRI Development Innovations LLC
Class:
OTHER
Study ID:
SCRI BRE 44
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
SCRI Development Innovations LLC
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |
| Eli Lilly and Company | INDUSTRY |